Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.
Rydex Health Care C RYHCX
- NAV / 1-Day Return 28.79 / +0.63 %
- Total Assets 22.5 Mil
-
Adj. Expense Ratio
- Expense Ratio 2.390%
- Distribution Fee Level High
- Share Class Type Level Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield —
- Turnover 268%
USD | NAV as of Apr 22, 2024 | 1-Day Return as of Apr 22, 2024, 10:18 PM GMT+0
Morningstar’s Analysis RYHCX
Will RYHCX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 26.0
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 4.21 | 1.1 Mil | Healthcare |
UnitedHealth Group Inc | 2.96 | 759,650 | Healthcare |
Johnson & Johnson | 2.92 | 750,578 | Healthcare |
Merck & Co Inc | 2.89 | 742,429 | Healthcare |
AbbVie Inc | 2.80 | 717,756 | Healthcare |
Thermo Fisher Scientific Inc | 2.30 | 590,706 | Healthcare |
Abbott Laboratories | 2.22 | 570,302 | Healthcare |
Danaher Corp | 2.05 | 527,037 | Healthcare |
Intuitive Surgical Inc | 1.90 | 487,398 | Healthcare |
Amgen Inc | 1.77 | 454,010 | Healthcare |